Wang HaiHong, Cheng BaoLi, Chen QiXing, Wu ShuiJing, Lv Chen, Xie GuoHao, Jin Yue, Fang XiangMing
Department of Anesthesiology, the First Affiliated Hospital, School of Medicine, Zhejiang University, QingChun Road, Hangzhou 310003, PR China.
Crit Care. 2008;12(4):R106. doi: 10.1186/cc6988. Epub 2008 Aug 17.
Gelsolin is an actin-binding plasma protein that is part of an 'actin-scavenging' system. Studies suggest that plasma gelsolin may play a crucial role in the pathophysiology of sepsis. Little is known about the course of plasma gelsolin levels over time in patients with severe sepsis. The aim of the study was to investigate plasma gelsolin levels in severe septic patients and to determine whether these levels predict the severity or clinical outcome of severe sepsis.
Ninety-one patients who were diagnosed with severe sepsis at admission to a surgical intensive care unit were enrolled, and admission plasma gelsolin levels were recorded. Plasma gelsolin levels were recorded daily in 23 of these patients. Daily plasma gelsolin levels were recorded in an additional 15 nonseptic critically ill patients. Fifteen volunteers served as healthy control individuals. Plasma gelsolin levels were measured using an enzyme-linked immunosorbent assay. Concentrations of IL-6, IL-10 and tumour necrosis factor (TNF)-alpha were also measured on intensive care unit admission.
The admission gelsolin levels were significantly decreased in severe sepsis (20.6 +/- 11.7 mg/l) compared with nonseptic critically ill patients (52.3 +/- 20.3 mg/l; P < 0.001) and healthy control individuals (126.8 +/- 32.0 mg/l; P < 0.001). Severe septic patients had increased IL-6 levels compared with nonseptic critically ill patients (20.0 +/- 10.7 pg/ml versus 11.4 +/- 13.9 pg/ml; P = 0.048), whereas no significant difference in IL-10 or TNF-alpha levels was observed (IL-10: 97.9 +/- 181.5 pg/ml versus 47.4 +/- 91.5 pg/ml, respectively [P = 0.425]; TNF-alpha: 14.2 +/- 13.9 pg/ml versus 6.9 +/- 5.3 pg/ml, respectively; P = 0.132). Survivors of severe sepsis exhibited substantial recovery of their depressed plasma gelsolin levels, whereas gelsolin levels in nonsurvivors remained at or below their depleted admission levels.
Plasma gelsolin may be a valuable marker for severe sepsis. Recovery of depleted plasma gelsolin levels correlated with clinical improvement. The prognostic role of plasma gelsolin in critical illness requires further investigation in a large cohort.
凝溶胶蛋白是一种肌动蛋白结合血浆蛋白,是“肌动蛋白清除”系统的一部分。研究表明,血浆凝溶胶蛋白可能在脓毒症的病理生理学中起关键作用。关于严重脓毒症患者血浆凝溶胶蛋白水平随时间的变化过程知之甚少。本研究的目的是调查严重脓毒症患者的血浆凝溶胶蛋白水平,并确定这些水平是否能预测严重脓毒症的严重程度或临床结局。
纳入91例入住外科重症监护病房时被诊断为严重脓毒症的患者,并记录入院时的血浆凝溶胶蛋白水平。其中23例患者每天记录血浆凝溶胶蛋白水平。另外15例非脓毒症重症患者也每天记录血浆凝溶胶蛋白水平。15名志愿者作为健康对照个体。使用酶联免疫吸附测定法测量血浆凝溶胶蛋白水平。在重症监护病房入院时还测量了白细胞介素-6(IL-6)、白细胞介素-10(IL-10)和肿瘤坏死因子-α(TNF-α)的浓度。
与非脓毒症重症患者(52.3±20.3mg/l;P<0.001)和健康对照个体(126.8±32.0mg/l;P<0.001)相比,严重脓毒症患者入院时的凝溶胶蛋白水平显著降低(20.6±11.7mg/l)。与非脓毒症重症患者相比,严重脓毒症患者的IL-6水平升高(20.0±10.7pg/ml对11.4±13.9pg/ml;P=0.048),而IL-10或TNF-α水平未观察到显著差异(IL-10:分别为97.9±181.5pg/ml对47.4±91.5pg/ml[P=0.425];TNF-α:分别为14.2±13.9pg/ml对6.9±5.3pg/ml;P=0.132)。严重脓毒症幸存者的血浆凝溶胶蛋白水平显著恢复到低于入院时的水平,而未幸存者的凝溶胶蛋白水平保持在或低于入院时耗尽的水平。
血浆凝溶胶蛋白可能是严重脓毒症的一个有价值的标志物。耗尽的血浆凝溶胶蛋白水平的恢复与临床改善相关。血浆凝溶胶蛋白在危重病中的预后作用需要在更大的队列中进一步研究。